Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P11362
UPID:
FGFR1_HUMAN
Alternative names:
Basic fibroblast growth factor receptor 1; Fms-like tyrosine kinase 2; N-sam; Proto-oncogene c-Fgr
Alternative UPACC:
P11362; A8K6T9; A8K8V5; C1KBH8; P17049; Q02063; Q02065; Q14306; Q14307; Q53H63; Q59H40; Q5BJG2; Q8N685; Q9UD50; Q9UDF0; Q9UDF1; Q9UDF2
Background:
Fibroblast growth factor receptor 1 (FGFR1), also known as Basic fibroblast growth factor receptor 1, Fms-like tyrosine kinase 2, N-sam, and Proto-oncogene c-Fgr, plays a pivotal role in embryonic development, cell proliferation, differentiation, and migration. It acts as a cell-surface receptor for fibroblast growth factors, essential for normal mesoderm patterning, axial organization, skeletogenesis, and the development of the gonadotropin-releasing hormone (GnRH) neuronal system.
Therapeutic significance:
FGFR1's involvement in diseases such as Pfeiffer syndrome, Hypogonadotropic hypogonadism 2, Osteoglophonic dysplasia, Hartsfield syndrome, Trigonocephaly 1, Encephalocraniocutaneous lipomatosis, and Jackson-Weiss syndrome highlights its therapeutic significance. Targeting FGFR1 could lead to innovative treatments for these genetic disorders.